Condition: Vulvar Adenocarcinoma · PDAC - Pancreatic Ductal Adenocarcinoma · Gastric Adenocarcinoma · Sponsor: Avacta Life Sciences Ltd
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
This description comes directly from the study's public registry record.
Avacta Clinical Team · +44 (0)20 3911 0353 · clinicaltrials@avacta.com
Always discuss trial participation with your own doctor first.
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| NEXT Oncology | Irving, Texas, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07454642